BR112012000865A2 - "composição e método para a modificação genética cosmética de células substancialmente intactas" - Google Patents

"composição e método para a modificação genética cosmética de células substancialmente intactas"

Info

Publication number
BR112012000865A2
BR112012000865A2 BR112012000865A BR112012000865A BR112012000865A2 BR 112012000865 A2 BR112012000865 A2 BR 112012000865A2 BR 112012000865 A BR112012000865 A BR 112012000865A BR 112012000865 A BR112012000865 A BR 112012000865A BR 112012000865 A2 BR112012000865 A2 BR 112012000865A2
Authority
BR
Brazil
Prior art keywords
cosmetic
composition
genetic modification
intact cells
substantially intact
Prior art date
Application number
BR112012000865A
Other languages
English (en)
Inventor
T Tabor Aaron
Watson Harmon John
Original Assignee
T Tabor Aaron
Watson Harmon John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Tabor Aaron, Watson Harmon John filed Critical T Tabor Aaron
Publication of BR112012000865A2 publication Critical patent/BR112012000865A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112012000865A 2009-07-17 2010-07-15 "composição e método para a modificação genética cosmética de células substancialmente intactas" BR112012000865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22651809P 2009-07-17 2009-07-17
PCT/US2010/042051 WO2011008904A1 (en) 2009-07-17 2010-07-15 Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance

Publications (1)

Publication Number Publication Date
BR112012000865A2 true BR112012000865A2 (pt) 2019-09-24

Family

ID=43449779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000865A BR112012000865A2 (pt) 2009-07-17 2010-07-15 "composição e método para a modificação genética cosmética de células substancialmente intactas"

Country Status (5)

Country Link
US (1) US9132202B2 (pt)
EP (2) EP2454368A4 (pt)
CN (1) CN102471769A (pt)
BR (1) BR112012000865A2 (pt)
WO (1) WO2011008904A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
CN103808940B (zh) * 2012-11-02 2017-06-06 株式会社芳珂 粗糙肌肤的评价方法
DE102013005361A1 (de) * 2013-03-28 2014-10-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Polyribonucleotid
WO2016105607A1 (en) * 2014-12-23 2016-06-30 Avon Products, Inc. Peptides and their use in the treatment of skin
US10086089B2 (en) 2015-09-18 2018-10-02 DNARx Systems and methods for nucleic acid expression in vivo
CN105944243A (zh) * 2016-05-12 2016-09-21 段俊丽 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置
JP2020511521A (ja) 2017-03-23 2020-04-16 ディーエヌエーアールエックス ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法
KR102021014B1 (ko) * 2018-11-21 2019-09-16 신민지 가슴 크림 제조방법 및 이에 의해 제조된 가슴 크림
CN109486771B (zh) * 2018-12-29 2021-02-12 深圳市旷逸生物科技有限公司 一种高表达sod3的cho细胞株构建方法及sod3蛋白纯化方法
KR20210151930A (ko) * 2019-04-12 2021-12-14 젤터, 인코포레이티드 재조합 엘라스틴 및 이의 제조
WO2022066845A1 (en) * 2020-09-23 2022-03-31 Aaron Thomas Tabor Novel genetic vector approaches for aesthetics, aesthetic plastic surgery, cosmetic dermatology, and other uses
EP4221679A1 (en) * 2020-09-30 2023-08-09 Geltor, Inc. Compositions comprising combinations of collagen or elastin polypeptides with active ingredients and methods of using same
RU2755346C1 (ru) * 2020-12-11 2021-09-15 Денис Григорьевич Кайгородов Композиция, содержащая фактор модернизации эпигенома, обладающая репаративным, онкопротекторным и противовоспалительным действием
CN114392245B (zh) * 2022-01-10 2023-10-10 自然资源部第三海洋研究所 多巴胺包埋纳米硒组装复合物及其制备方法
WO2023230466A1 (en) * 2022-05-23 2023-11-30 Lutsenka Svetlana Compositions and methods for treating wilson's disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (en) 1983-04-25 1993-09-29 Chiron Corporation Hybrid dna synthesis of mature insulin-like growth factors
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US4769328A (en) 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US4849407A (en) 1986-08-13 1989-07-18 Zymogenetics, Inc. Biologically active mosaic proteins
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5045633A (en) 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4760096A (en) 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
US5219759A (en) 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US5158875A (en) 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1992004363A1 (en) 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
JPH05506673A (ja) 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
NZ244980A (en) 1991-11-15 1994-07-26 Delta West Pty Ltd Injection device operated by a deformable plastics ampoule
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
ES2227527T3 (es) 1993-06-29 2005-04-01 Chiron Corp Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
CA2280997C (en) 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US6228839B1 (en) 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
ATE246518T1 (de) 1998-06-02 2003-08-15 Glaxo Group Ltd Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
CA2377371A1 (en) 1999-06-22 2000-12-28 David N. Herndon Enhanced wound coverage to enhance wound healing
WO2001002433A1 (en) * 1999-07-02 2001-01-11 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6861239B1 (en) 1999-09-20 2005-03-01 New York University Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
EP1130086A1 (en) * 2000-02-18 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genetically engineered keratinocytes and toxicity assay using said keratinocytes
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
CA2457781A1 (en) * 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
US6856185B2 (en) 2001-10-23 2005-02-15 Arris International, Inc. Simple RMS to DC converter
EP1375646A1 (en) * 2002-06-21 2004-01-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genetically engineered keratinocytes expressing at least one growth factor and/or activated EGF receptor, skin equivalent comprising said keratinocytes and toxicity assay using said keratinocytes
DE10238298A1 (de) 2002-08-21 2004-03-04 Beiersdorf Ag Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
DE10254214A1 (de) 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
US7511025B2 (en) * 2004-06-16 2009-03-31 Trustees Of Dartmouth College Compositions and methods for inhibiting the synthesis or expression of MMP-1
AU2006206267A1 (en) 2005-01-21 2006-07-27 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
US20080234194A1 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US9045759B2 (en) * 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number

Also Published As

Publication number Publication date
EP2454368A1 (en) 2012-05-23
CN102471769A (zh) 2012-05-23
EP4219708A3 (en) 2023-10-11
WO2011008904A1 (en) 2011-01-20
EP2454368A4 (en) 2013-01-09
US20120115938A1 (en) 2012-05-10
US9132202B2 (en) 2015-09-15
EP4219708A2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
BR112012000865A2 (pt) "composição e método para a modificação genética cosmética de células substancialmente intactas"
HK1144667A1 (en) Cosmetic auxiliary patch material and method of cosmetizing therewith
BRPI0810929A2 (pt) "método para proteger"
FI20096288A0 (fi) Formulations and methods for culturing stem cells
BRPI0814425A2 (pt) Diferenciação de células-tronco embrionárias humanas
ZA201006586B (en) Plant disease controlling composition and method for controlling plant disease
EP2464755A4 (en) METHODS AND KITS FOR MARKING THE 3 'END OF RNA
BRPI1009989A2 (pt) "método de produção de viga de torção e viga de torção"
ES2674239T8 (es) Medios para células madre pluripotentes carentes de alimentadores que contienen suero humano
EP2044927A4 (en) COSMETIC PRODUCT AND PROCESS FOR PRODUCTION THEREOF
EP2434879A4 (en) COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES
EP2047842A4 (en) COSMETIC PRODUCT AND METHOD FOR PRODUCING THE SAME
EP2192907A4 (en) ERYTHROPOETIN AND FIBRONECTINE COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS
BR112013003385A2 (pt) "composições e métodos para produzir células dentríticas"
PL2367424T3 (pl) Kompozycja do zwalczania chorób roślin oraz sposób zwalczania chorób roślin
BRPI0818102A2 (pt) "composição e método para resfriar a pele e controlar a sudorese na pele"
EP2200638A4 (en) TRANSFECTION PROCEDURES AND COMPOSITIONS FOR THIS
BR112012004668A2 (pt) "composição e processo"
EP2517165A4 (en) MEANS AND METHODS FOR INVESTMENT PORTFOLIO MANAGEMENT
ZA201103798B (en) Composition for controlling plant diseases and method for controlling plant diseases
ZA201103412B (en) Composition and method for controlling plant diseases
BR112012009820A2 (pt) "substituto de refeição e processo de preparação de um substituto de refeição "
BRPI1011599A2 (pt) "arranjo de bateria e método para a produção de um arranjo de bateria"
ZA201301903B (en) Plant disease controlling composition and method for controlling plant disease
EG26710A (en) Installation and method to eliminate plant diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.